Growth Metrics

Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2025)

Sol-Gel Technologies (SLGL) reported Total Non-Current Liabilities of $935000.0 for Q4 2025, down 45.35% year-over-year from $1.7 million in Q4 2024, and down 61.3% on a QoQ basis from $2.4 million in Q3 2025.

Sol-Gel Technologies (SLGL) has 10 years of Total Non-Current Liabilities data on file, last reported at $935000.0 in Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 45.35% year-over-year to $935000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $935000.0 (down 45.35% YoY) and the FY2025 annual result came in at $935000.0, down 45.35% from the prior year.
  • Total Non-Current Liabilities slipped to $935000.0 in Q4 2025 per SLGL's latest filing, from $2.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $2.5 million in Q2 2025 and bottomed at $935000.0 in Q4 2025.
  • The 5-year median for Total Non-Current Liabilities is $1.9 million (2021), against an average of $1.8 million.
  • The widest annual swing landed in 2023, when Total Non-Current Liabilities surged 95.3%; it then slumped 45.35% in 2025.
  • Tracing SLGL's Total Non-Current Liabilities over 5 years: stood at $1.9 million in 2021, then slumped by 42.93% to $1.1 million in 2022, then surged by 95.3% to $2.1 million in 2023, then decreased by 19.33% to $1.7 million in 2024, then tumbled by 45.35% to $935000.0 in 2025.
  • Per Business Quant, the three latest SLGL Total Non-Current Liabilities figures stand at $935000.0 (Q4 2025), $2.4 million (Q3 2025), and $2.5 million (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 11.03 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - 42,980.09
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 95.20 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - 110.28 Mn
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 5.87 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 7.32 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 4.05 Bn
10 Sol-Gel Technologies 205.76 Mn 194.73 Mn - 935,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 935,000.00
Sep 30, 2025 2.42 Mn
Jun 30, 2025 2.47 Mn
Mar 31, 2025 2.32 Mn
Dec 31, 2024 1.71 Mn
Sep 30, 2024 1.74 Mn
Jun 30, 2024 1.90 Mn
Mar 31, 2024 2.04 Mn
Dec 31, 2023 2.12 Mn
Sep 30, 2023 2.23 Mn
Jun 30, 2023 1.14 Mn
Mar 31, 2023 1.06 Mn
Dec 31, 2022 1.09 Mn
Sep 30, 2022 1.22 Mn
Jun 30, 2022 1.41 Mn
Mar 31, 2022 1.72 Mn
Dec 31, 2021 1.90 Mn
Sep 30, 2021 1.86 Mn
Jun 30, 2021 2.00 Mn
Mar 31, 2021 2.09 Mn
Dec 31, 2020 2.35 Mn
Sep 30, 2020 2.09 Mn
Jun 30, 2020 2.20 Mn
Mar 31, 2020 2.26 Mn
Dec 31, 2019 2.33 Mn
Sep 30, 2019 1.17 Mn
Jun 30, 2019 1.28 Mn
Mar 31, 2019 1.39 Mn
Dec 31, 2018 878,000.00
Sep 30, 2018 907,000.00
Mar 31, 2018 932,000.00
Dec 31, 2017 810,000.00
Dec 31, 2016 694,000.00